BCL2 and hepatocellular carcinoma: Similarly, our findings indicate a decrease in the drug score of WEHI-539 (a Bcl-2 inhibitor; Figure 3D) and LCL 161 (an IAP inhibitor; Figure 3E) in HCC tissues with the XIRP2 mutation.